Atezolizumab Plus Bevacizumab With HCC and HBV Infection

NAActive, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 12, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Atezolizumab

Atezolizumab 1200 mg IV on day 1 every 3 weeks

DRUG

Bevacizumab

Bevacizumab 15 mg/kg IV on day 1 every 3 weeks

Trial Locations (7)

Unknown

Chang Gung Memorial Hospital, Linkou District

China Medical University Hospital, Taichung

Taichung Veterans General Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

Mackay Memorial Hospital, Taipei

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Mackay Memorial Hospital

OTHER

collaborator

Changhua Christian Hospital

OTHER

collaborator

China Medical University Hospital

OTHER

collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

collaborator

Taichung Veterans General Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER